midgardfinance.com
LightNews LightNews
midgardfinance.com
midgardfinance.com
@midgardfinance.com
120 followers 180 following 410 posts
- Dividend Growth
- Small Cap Value
- European Investor 🇪🇺
- Nordic Stocks 🇩🇰🇳🇴🇸🇪🇫🇮🇮🇸🇫🇴🇬🇱
Posts Replies Media Videos
midgardfinance.com
They can be a bit tricky to distinguish from each other. If you made these with matplotlib, then there is a module that allows you to draw a line between the label and the data point. I can't remember the name.
December 7, 2025 at 1:16 PM
midgardfinance.com
Oracle is an interesting choice. I hope both prove to be good investments for you 💙
November 29, 2025 at 8:27 AM
midgardfinance.com
What exactly did you see happen to Adobe and Duolingo?
November 27, 2025 at 10:29 PM
midgardfinance.com
Would you buy a company spending over $2B on buybacks every quarter, sitting at a ~$130B market cap, with steady fundamentals and real AI tools actually shipping?

Because... that company is literally here.

$ADBE #ADBE 🎨💻🔥
November 27, 2025 at 10:18 PM
midgardfinance.com
How much would you pay for a company with...

• forward EPS ~24 USD
• ROIC ~28%
• gross margin ~89%
• operating margin ~36%
• recurring revenue ~90% 🔁
• 10y revenue CAGR ~15% 📊
• FCF margin ~40% 💵
• R&D spend ~18% of revenue 🧪

Asking for a friend called $ADBE (share price ~320 USD) 📈🔥
November 27, 2025 at 8:11 PM
midgardfinance.com
Pandora Q3
• ROIC: 43% 🔥
• Silver: ~32 USD/oz 🪙🚀
• Gold: ~2,900–4,000 USD/oz 📈
• US LFL: +6% 🇺🇸
• Europe LFL: -1% 🇪🇺
• RoP LFL: +6% 🌏
• Australia LFL: +4% 🇦🇺
• Net store openings (12m): +65 CS, +85 SiS 🏬
• China stores: -33 QoQ, -60 YoY 🇨🇳
#PNDORA #PNDORA.CO #Pandora #2025Q3
November 18, 2025 at 12:24 PM
midgardfinance.com
Pandora Q3
• EBIT hit: ~380bp from silver, gold, FX, tariffs 🪙📉
• Gross margin drag: ~280bp 🧊
• Structural lifts: pricing +, mix +, network + 🧩
• EBIT margin: 14.0% (vs 16.1%) ⚙️
• 2025 EBIT guidance: ~24% 🎯
#PNDORA #PNDORA.CO #Pandora #2025Q3
November 18, 2025 at 12:24 PM
midgardfinance.com
Pandora Q3
• Organic growth: +6% 🚀
• LFL: +2% 📈
• Revenue: DKK 6.27B 💎
• Gross margin: 79.3% (-80bp) 📉
• EBIT margin: 14.0% (-210bp) ⚙️
• EPS: 6.3 DKK (-14%, +5% FX-adjusted) 🌐
• US LFL: +6% 🇺🇸
• Europe LFL: -1% 🇪🇺
• RoP LFL: +6% 🌍
#PNDORA #PNDORA.CO #Pandora #2025Q3
November 18, 2025 at 12:24 PM
midgardfinance.com
Pandora ($PNDORA.CO) reports Q3 earnings Wednesday.
Higher gold and silver prices may pressure margins, but network expansion and strong US demand support the long-term thesis.
Still one of the best-run Nordic consumer brands with solid ROIC and pricing power.

#Pandora #PNDORA #OMXN40 #NordicStocks
November 3, 2025 at 9:08 PM
midgardfinance.com
Apple quarterly expenses (USDm)

COGS 52.8% -70bp
R&D 8.7% -80bp
SG&A 6.9% -20bp
November 2, 2025 at 1:00 PM
midgardfinance.com
Apple quarterly revenue (USDm)

🌎 Americas 44,192 +6%
🌍 Europe 28,703 +15%
🌏 Greater China 14,493 -4%

Total 102,466 +8%
November 2, 2025 at 1:00 PM
midgardfinance.com
Apple quarterly revenue (USDm)

📱 iPhone 49,025 +6%
⌚️ Wearables 9,013 -0%
💻 Mac 8,726 +13%

Services 28,750 +15%

Total 102,466 +8%

#AAPL
November 2, 2025 at 12:57 PM
midgardfinance.com
The chart shows the estimated earnings growth of S&P 500 index and different sectors within it for Q3 2025 - www.reuters.com/graphics/GLO...
October 13, 2025 at 5:56 AM
midgardfinance.com
Murder on the Orient Express anyone? 🚂🔪🇺🇸
August 2, 2025 at 8:26 PM
midgardfinance.com
💻☁️ Cloud Kings 2025 (Q2 revenue)

MSFT $47B +27% 👑
Google Cloud $14B +32% 🚀
AWS $31B +17% 📈
Snowflake $1B +26% ❄️ (Q1)

Microsoft, Google and Snowflake still on turbo 🐎

#CloudComputing #TechStocks #MSFT #GOOG #AMZN #SNOW #CRM #ADBE #ORCL #IBM #BigTech
Time-series bar chart (2017 Q1 → 2025 Q2) of cloud-segment revenue by company. Bars fade from light (old) to dark (latest). Microsoft leads ($47 B), followed by AWS ($31 B), Google Cloud ($14 B). Oracle, Salesforce, Adobe trail, Snowflake smallest ($1 B) but fast-growing.
August 1, 2025 at 4:51 PM
midgardfinance.com
🇫🇷🇪🇺 LVMH

Q2 organic revenue growth and profit margin change:
👜📉 Fashion & Leather Goods -9% -4% ⚠️
💄📈 Selective Retailing +4% +1%
💍📉 Watches & Jewelry 0% -2%
🥃📉 Wines & Spirits -4% -8%
🧴📈 Perfumes & Cosmetics +1% -1%

#LVMH #MC.PA #$MC.PA #LuxuryGoods #CAC40 #FranceStocks #Fundamentals
Bar chart showing LVMH's trailing twelve-month (TTM) revenue by business segment from Q4 2023 to Q2 2025. Fashion & Leather Goods is the largest segment but shows a slight decline. Selective Retailing trends upward, while Wines & Spirits steadily decline. Perfumes & Cosmetics and Watches & Jewelry remain relatively stable.
July 28, 2025 at 6:47 PM
midgardfinance.com
🇳🇿🥇
🇺🇸🥈
🇮🇳🥉
worldperatio.com 🥝🏆
July 28, 2025 at 5:57 PM
midgardfinance.com
Mixed bag.
July 26, 2025 at 5:38 PM
midgardfinance.com
🇪🇺🩺 STOXX 600 heat check
📊⬇️ 5‑yr median ROIC vs fwd rev growth

🔍 Closer look?

🇩🇰 Novo Nordisk 💉
⚠️ Semaglutide cliff early 2030s 📉

🇩🇰 Pandora 💍
⚠️ 1/3 US sales 🇺🇸
⚠️ Thailand tariffs 🇹🇭

🇳🇱 ASML
⚠️ Export curbs 🛂
⚠️ China slump 🇨🇳

#NOVO-B.CO #PNDORA.CO #ASML.AS
Bubble scatter plot titled “STOXX Europe 600”. X‑axis shows 5‑year median ROIC (‑20 % → 50 %), y‑axis shows forward revenue growth (‑5 % → 45 %). Each company in the index is a bubble: size ≈ free‑cash‑flow yield, colour = forward P/E (dark blue = low, yellow = high). Most bubbles cluster near the origin. Clear outliers on the right include NOVO‑B.CO (large teal bubble at ROIC ≈ 50 %, growth ≈ 13 %), ASML.AS, PNDORA.CO and AXFO.ST, all with ROIC in the mid‑30 % range and single‑digit growth. Colour bar and Midgard Finance watermark sit on the right.
July 25, 2025 at 10:18 AM
midgardfinance.com
2/2 #GOOG Alphabet Q2 2025

💸 CapEx (PPE) $22.4B (+70% YoY) - AI data centers 📈
🔁 Buybacks $13.6B (‑13% YoY)
🪙 Dividends $2.54B (+3.1% YoY)
🧪 R&D $13.8B (+16% YoY)

Charts ⬇️
#$GOOG #AI #AIInfra #CapEx #Buybacks #Dividends #TechStocks
CapEx bars spike to $22.4B in Q2’25 (+70% YoY); sharp jump since 2023, reflecting AI datacenter spend. Share repurchase outlays at $13.6B (‑13% YoY); bars show a slight decline vs. 2024 peaks. Dividend payments around $2.54B (+3% YoY); four similar-height bars since program began in 2024. R&D expense rises to $13.8B (+16% YoY); consistent upward trend with a noticeable jump in 2024–2025.
July 24, 2025 at 10:57 PM
midgardfinance.com
1/2 #GOOG Alphabet Q2 2025

💰 Rev $96.4B (+14% YoY)
🔎 Search ~$54.2B (+12%)
▶️ YouTube ads ~$9.8B (+13%)
☁️ Cloud $13.6B (+32%)

Charts ⬇️
#$GOOG #AlphabetEarnings #AI #GoogleCloud #Search #YouTube
Bar chart of quarterly revenue (2014–Q2’25) rising to $96.4B, a record and +14% YoY; current quarter highlighted. Search revenue bars trend upward to ~$54.2B in Q2’25 (+12% YoY); steady growth visible since 2023. YouTube ads revenue climbs to ~$9.8B (+13% YoY); gradual recovery from 2022 dip. Google Cloud revenue accelerates to $13.6B (+32% YoY); steep upward slope over last 8 quarters.
July 24, 2025 at 10:57 PM
midgardfinance.com
Slides from Evolution AB 🇸🇪

- Net rev €524.3 m (+3%) 📈
- EBITDA margin 65.9%
- Live casino flexed +3.6% 📈
- New studios just dropped in 🇵🇭 & 🇧🇷
- EU rev -5% on 🇬🇧 ring-fencing 📉
- 110+ fresh games queued for 2025
- Margin guide 66-68% still locked
- €500 m buyback & €2.80 div teased 💸

#EVO #EVO.ST
A snowy, cartoon-style “ice-fishing for profits” scene branded Evolution AB leads into two content blocks: • Bullet list of Q2 25 financial and operational highlights (net revenue €524.3 m +3 %, EBITDA margin 65.9 %, live casino +3.6 %, first studios in Philippines & Brazil, etc.). • Two small photos: ribbon-cutting team in red dresses between gold balloons, and a smiling female game-show host beside a roulette-like wheel showing the number 6. Below, twin bar charts show head-count rising to ~22.4 k and game-round-index climbing to ~386 with brief YoY notes. Four blue bar-chart panels track revenue trends: Europe dips to ~€180 m, Asia climbs to ~€210 m, North America edges up to ~€74 m, Latin America to ~€38 m. Comment boxes call out % changes, new studios, and regulatory notes. A wide bottom chart stacks quarterly net revenue and adjusted EBITDA from Q2 21 to Q2 25, with a black line showing margin sliding from ~70 % to 65.9 %. Bullet list forecasts 66-68 % margins, 110+ new games in 2025, and state-of-the-art studios in Brazil and the Philippines. Capital items: 2025 capex €140 m, dividend floor 50 % (proposed €2.80/share), and €500 m buyback intent. Right side: photo of a stylish female dealer at a green gaming table framed by retro control-panel lights.
July 17, 2025 at 11:23 AM
midgardfinance.com
📉 CagriSema 2.4/2.4 mg also shows strong results in people with T2D

−15.7% mean weight loss vs −3.1% placebo at 68 weeks
💪

Combo still delivers, even with insulin resistance on board.

#CagriSema #T2D #Obesity #GLP1 #NEJM #NovoNordisk #ADA2025 #Diabetes
Four panels from a clinical trial show the effects of once-weekly CagriSema vs placebo in adults with type 2 diabetes and obesity. Panel A and B: Line charts show weight loss over 68 weeks with CagriSema achieving −15.7% vs −3.1% placebo. Panel C and D: Bar charts show proportions of patients achieving ≥5%, ≥10%, ≥15%, and ≥20% weight loss. CagriSema dramatically outperforms placebo, with 29% reaching ≥20% loss vs 0.2% on placebo (trial-product estimand). Confidence intervals and statistical significance (P<0.001) are reported throughout.
June 22, 2025 at 3:18 PM
midgardfinance.com
📊 CagriSema 2.4/2.4 mg just dominated in REDEFINE-1 💥💉

−22.7% mean weight loss at 68 weeks vs −2.3% placebo.

Best-in-class? Combo GLP-1 + amylin is setting new records 🚀

#CagriSema #Obesity #NEJM #NovoNordisk #ADA2025 #NVO
Bar and line charts from REDEFINE-1 show body weight change over 68 weeks for patients receiving CagriSema, semaglutide, cagrilintide, or placebo. The combination (CagriSema) leads to the greatest weight loss (−22.7%) compared with semaglutide (−16.1%), cagrilintide (−11.8%), and placebo (−2.3%). Panel A presents mean percent weight change by group; Panel B shows time-course curves of weight reduction. CagriSema consistently outperforms all other arms.
June 22, 2025 at 3:18 PM
midgardfinance.com
Oral amycretin also flexed 💊💪

In just 12 wks, −13% weight (2×50 mg), −10% (50 mg), placebo −1%. No plateau. Mild GI side-effects. Dual-agonist combo could reshape obesity treatment. 🌊

#NovoNordisk #Amycretin #ADA2025
Clinical trial results showing bodyweight changes with oral amycretin vs placebo. Panel A plots mean bodyweight (kg) from screening through day 105. Amycretin groups (50 mg, 2×50 mg, 2×25 mg) all show clear weight reduction compared to stable placebo. Panel B illustrates percentage weight change from baseline (day 1) to day 105, highlighting dose-dependent effects. Greatest loss at 2×50 mg, followed by 2×25 mg, then 50 mg; minimal change with placebo. Panel C provides bar-chart summaries of day-85 results: 50 mg amycretin shows –10.4%, 2×50 mg –13.1%, 2×25 mg –12.2%, and placebo –1.2%. Estimated treatment differences vs placebo: –9.2% (50 mg), –11.8% (2×50 mg), and –11.1% (2×25 mg), all statistically significant with clear confidence intervals. The data demonstrate amycretin's robust, dose-responsive weight-loss potential compared to placebo over 12 weeks without plateau.
June 21, 2025 at 9:26 AM